GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » Total Current Liabilities

Gelesis Holdings (Gelesis Holdings) Total Current Liabilities : $50.24 Mil (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Gelesis Holdings's total current liabilities for the quarter that ended in Jun. 2023 was $50.24

Gelesis Holdings Total Current Liabilities Historical Data

The historical data trend for Gelesis Holdings's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gelesis Holdings Total Current Liabilities Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
Total Current Liabilities
69.17 50.68

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.71 51.49 50.68 49.38 50.24

Gelesis Holdings Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Gelesis Holdings's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=13.861+35.954
+Other Current Liabilities+Current Deferred Liabilities
=0.13+0.738
=50.68

Gelesis Holdings's Total Current Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=15.591+33.912
+Other Current Liabilities+Current Deferred Liabilities
=0+0.738
=50.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Gelesis Holdings Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gelesis Holdings (Gelesis Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » Total Current Liabilities
Comparable Companies
RBSH PPCB RGMP CALA ONCSQ RGIN RGTPQ RSPI MYMX HGEN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Website
https://www.gelesis.com
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Executives
Raju S Kucherlapati director 77 LOUIS PASTEUR AVENUE, BOSTON MA 02115
Bomsmaster Llc 10 percent owner 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510
Paul R. Fonteyne director C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Hpso Spv Ltd 10 percent owner SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA
Alessandro Sannino officer: Lead Project Scientist C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Dominic Perks director GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116
David A. Pass officer: Chief Op. & Comm. Officer GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116
Elaine Chiquette officer: Chief Scientific Officer C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Jane Wildman director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Harry L. Leider officer: Chief Medical Officer C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Clayton Christopher director 2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704
Health Plc Puretech 10 percent owner 6 TIDE STREET, SUITE 400, BOSTON MA 02210
Ssd2, Llc 10 percent owner 142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511
Yishai Zohar director, officer: President & CEO C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Elon Boms 10 percent owner C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510

Gelesis Holdings (Gelesis Holdings) Headlines

From GuruFocus

Gelesis Reports Upcoming Participation in Wolfe Research's Annual Consumer Growth Conference

By Business Wire Business Wire • 11-21-2022

Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET

By Business Wire Business Wire • 08-17-2022

Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

By Business Wire Business Wire • 11-07-2022

Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022

By Business Wire Business Wire • 05-09-2022

Gelesis to Report Second Quarter 2022 Financial Results on August 15, 2022

By Business Wire Business Wire • 08-04-2022

Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics

By Business Wire Business Wire • 11-02-2022

Gelesis to Participate in Upcoming Investor Conferences

By Business Wire Business Wire • 05-18-2022

Gelesis� Releases Preliminary National Launch Results for Plenity�: Record-Breaking Levels of Prescriptions and Online Traffic

By Business Wire Business Wire • 03-16-2022

Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study

By Business Wire Business Wire • 06-05-2022

Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis' Oral Hydrogel Treatment GS200 at Obesity Week

By Business Wire Business Wire • 11-01-2022